###### Strengths and limitations of this study

-   A narrative literature review of registered clinical trials in children.

-   Explicit reproducible methodology.

-   Search strategy limited to ClinicalTrials.gov and EudraCT. Entirety of clinical research in this field might not have been captured.

-   Search strategy was limited to open clinical trials. Active but not yet recruiting trials were not captured.

Introduction {#s1}
============

Widespread unlicensed and off-label prescribing in paediatrics persists---as high as 11.4% and 46.5%, respectively---yet the paucity of clinical research involving children that is conducted to inform optimal drug dosing, licensing and labelling remains a problem.[@R1] For certain medicines, drug efficacy can be extrapolated from adult data provided that the pathology and drug exposure are the same or sufficiently similar in children as in adults.[@R2] Although differences in drug pharmacokinetics (PK) in neonates and children can lead to adverse reactions that are not seen in adult populations, these are very rare.[@R4] Suboptimal antibiotic dosing, including underdosing and overdosing, can lead to toxicity and treatment failure and may drive antimicrobial resistance by encouraging selection pressures on drug-resistant strains of bacteria.[@R5]

Since antibiotics are the most commonly prescribed medicines in children, it is important to maximise our understanding of their PK profiles to help determine optimal drug dosing and ultimately to improve outcomes.[@R6] In the last decade, several initiatives have been established to encourage paediatric medicines research, bridging the gap between adult and paediatric drug development plans. Such initiatives include the Paediatric Regulation (Paediatric Investigation Plans (PIPs), introduced by the European Medicines Agency (EMA),[@R7] and Pediatric Study Plans, by the US Food and Drug Administration (FDA)).[@R8] Despite this, there have been few advances in antibiotic development for this population.[@R9]

The global status of clinical research on antibiotics in paediatrics is unknown. Using registered records of clinical trials (CTs) on *ClinicalTrials.gov*, this review aims (1) to summarise the current global status of registered antibiotic research in children and neonates and (2) to stimulate discussion and collaboration among the relevant stakeholders on the neglect of antibiotic research in children.

Methods {#s2}
=======

Data sources {#s2a}
------------

The *ClinicalTrials.gov* registry (last accessed 8 November 2016) is an international platform for the registration of CTs. It is a web-based registry, developed in 2000 by the National Institutes of Health and the FDA, to which trials from 50 states and 163 countries around the world are registered. Information provided for each trial is updated periodically by the trial's sponsoring organisation. The database has a specific child filter, which uses a key word paradigm to select all registered trials recruiting patients/participants up to 18 years of age.

Study selection {#s2b}
---------------

Our records were identified using suitable key word searches, in which the final search terms were (antimicrobial\* OR antibiotic\* OR anti-infective agent\*) AND Child AND Open Studies. All identified trials were filtered manually using inclusion and exclusion criteria. Interventional and observational trials on antimicrobials recruiting children up to 18 years of age were considered eligible for inclusion. No specific temporal filter was applied since only open or ongoing clinical trials were of interest. The following records, which were not investigating one or more antibiotics, were excluded: trials of antiseptics, antifungals, antiprotozoals, antivirals and probiotics or prebiotics. The following records, which were investigating an antibiotic, were excluded: trials involving tuberculosis, malaria, cystic fibrosis, HIV, febrile neutropenic patients, topical or inhalational treatments and prophylactic antibiotics or records investigating alternative use for antibiotics (eg, as an anti-inflammatory agent).

The searches were conducted by GT. All eligible records were identified via manual filtering by GT, CIB, LF and MS, and any disagreements regarding inclusion and exclusion of records were resolved through discussion.

Data extraction {#s2c}
---------------

The following information was collected from the included records: unique ClinicalTrials.gov identifier (NCT number), recruitment status, study design, trial phase, study sponsor, age group and sex eligibility, clinical indication, geographic region of recruitment, antibiotic being investigated and endpoint classification. Outcomes were categorised as safety, efficacy or PK. Economic setting (based on geographic region of recruitment) was classified using The World Bank classification to differentiate between low-income countries (LICs), lower income and middle-income countries (LMICs), upper middle-income Countries (UMICs) and high-income countries (HICs).[@R10]

The specific class of antibiotic studied in each trial was identified and classified using the WHO Anatomical, Therapeutic, and Chemical classification and Defined Daily Dose (ATC/DDD) index.[@R11] To investigate whether novel antibiotics are being studied in paediatric populations, the antibiotics currently studied in children were compared with the *Pew Charitable Trusts Antibiotics Currently in Clinical Development* pipeline, which identifies novel antibiotics currently under development for the US market.[@R12]

Results {#s3}
=======

Our search identified 1056 records. Six hundred and three records were excluded on title because they were studies not involving an antimicrobial. Four hundred and fifty-three records were investigating one or more antimicrobials and recruiting children below 18 years of age. Among the 195 trials investigating antibiotics, 76 fulfilled our inclusion and exclusion criteria and were included in the final analysis. Reasons for exclusion are summarised in [figure 1](#F1){ref-type="fig"}. Details of included studies can be found in online [supplementary file 1](#SP1){ref-type="supplementary-material"}.
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![Flow chart. Clinical trial selection process.](bmjopen-2017-016293f01){#F1}

All 76 CTs identified were open as of 8 November 2016, and 63 (83%) of these were recognised as recruiting participants on this date ([table 1](#T1){ref-type="table"}). All trials stated recruitment of both male and female participants.

###### 

Characteristics of clinical trials

  Characteristic       Category                                     Number of studies, n (%)
  -------------------- -------------------------------------------- --------------------------
  Age group            Preterm neonates                             1 (1)\*
                       Neonates (total)                             23 (30)
                       Infants and toddlers                         52 (68)
                       Children                                     58 (76)
                       Adolescents                                  54 (71)
  Recruitment status   Recruiting                                   63 (83)
                       Not yet recruiting                           13 (17)
  Study design         Interventional                               66 (87)
                       Observational                                10 (13)
  Trial phase†         Phase 1                                      10 (15)
                       Phases 1--2                                  1 (2)
                       Phase 2                                      9 (14)
                       Phases 2--3                                  3 (5)
                       Phase 3                                      10 (15)
                       Phase 4                                      23 (39)
                       Not specified                                10 (15)
  Sponsor              Industry                                     26 (34)
                       Non-profit                                   50 (66)
  Geographic region    Africa                                       8 (11)
                       Asia                                         16 (21)
                       Europe                                       22 (29)
                       Latin America                                6 (8)
                       North America                                34 (45)
                       Oceania                                      5 (7)
  Antibiotic class     J01A Tetracycline                            4 (5)
                       J01C Beta-lactam, penicillin                 25 (33)
                       J01D Other beta-lactam                       22 (29)
                       J01E Sulfonamides and trimethoprim           7 (9)
                       J01F Macrolide, lincosamide, streptogramin   14 (18)
                       J01G Aminoglycoside                          2 (3)
                       J01M Quinolone                               8 (11)
                       J01X Other antibiotic classes‡               21 (28)
                       J01 Not specified                            2 (3)

Totals for age group, geographic region and antibiotic class do not add up to total number of clinical trials (76) as some trials contributed to more than one subgroup.

\*Seven further trials mentioned inclusion of preterm babies in the inclusion criteria.

†Trial phase % based on percentage of interventional trials.

‡J01X includes glycopeptides, polymyxins, imidazole and nitrofuran derivatives.

Age group {#s3a}
---------

Twenty-three of the 76 trials (30%) were recruiting newborns (0--28 days). One of these 23 trials focused solely on recruiting preterm newborns (a further 7 CTs mentioned inclusion of preterm newborns in inclusion criteria). Of the remaining records, 52 (68%) were recruiting infants and toddlers (28 days--23 months), 58 (76%) children (2--11 years) and 54 (71%) adolescents (11--18 years). Twenty-nine (38%) trials did not focus solely on the recruitment of children or neonates, with age ranges also spanning across adult populations.

Study type {#s3b}
----------

Interventional trials were most frequently identified (n=66, 87%) with only 10 (13%) observational trials noted. Of the interventional trials, the majority were in the later stages of development; 10 (13%) in phase 1, 1 (2%) between phases 1 and 2, 9 (14%) in phase 2, 3 (5%) between phase 2 and phase 3, 10 (15%) in phase 3 and 23 (35%) in phase 4. In 10 (15%) cases, a trial phase was not specified.

Sponsor and endpoint classification {#s3c}
-----------------------------------

Fifty trials (66%) were sponsored by non-profit organisations (being university, hospital or government funded), and 26 trials were sponsored by industry (34%). The endpoint classification of the majority of trials (n=43, 57%) was reported as efficacy ([table 2](#T2){ref-type="table"}). A greater proportion (n=34, 68%) of non-profit studies measured the efficacy of the drugs as the primary endpoint, with less emphasis on collection of PK or safety data (n=16, 32%). In comparison, pharmaceutical-led trials focused on early PK and safety studies over the drug's efficacy (n=17, 65% vs n=9, 35%, respectively).

###### 

Clinical trial endpoint classification of identified clinical trials stratified by trial sponsor

  Endpoint classification   Industry   Non-profit   Total (%)
  ------------------------- ---------- ------------ -----------
  Efficacy                  9          34           43 (57)
  Safety                    10         2            12 (16)
  PK                        7          14           21 (28)

Endpoint classification determined by planned primary outcomes.

PK, pharmacokinetics.

Geographic region {#s3d}
-----------------

The most frequently recruiting geographic region was North America (n=34, 45%). Twenty-two (29%) trials recruiting in Europe and 16 (21%) in Asia were identified, 6 (8%) in Latin America, 8 (11%) in Africa and 5 (7%) in Oceania. Most trials were recruiting in HICs (n=54, 71%), with fewer trials recruiting in LICs (n=4, 5%), LMICs (n=4, 5%), UMICs (n=11, 14%) or a combination of UMICs and HICs (n=3, 4%).

Indication {#s3e}
----------

The most common treatment indications investigated were lower respiratory tract infection (n=12, 16%) and sepsis (n=11, 14%), followed by upper respiratory tract infection (n=8, 11%), intra-abdominal infection (IAI) (n=8, 11%), urinary tract infection (UTI) (n=7, 9%), complicated skin and soft tissue infection (cSSTI) (n=6, 8%), central nervous system (CNS) infection (n=3, 4%) and bone and joint infection (n=1, 1%) ([table 3](#T3){ref-type="table"}).

###### 

Clinical indication of identified clinical trials stratified by age group being recruited

  Indication                          Total (%)   Age group                  
  ----------------------------------- ----------- ----------- ---- ---- ---- ----
  Unspecified bacterial infection     18 (24)     --          11   15   15   14
  Lower respiratory tract infection   12 (16)     1           3    12   13   5
  Sepsis                              11 (14)     --          6    9    9    11
  Upper respiratory tract             8 (11)      --          1    5    9    7
  Intra-abdominal infection           8 (11)      --          3    5    5    7
  Urinary tract infection             7 (9)       --          2    6    7    6
  Skin and soft tissue infection      6 (8)       --          3    4    4    8
  CNS infection                       3 (4)       --          1    4    4    4
  Bone and joint Infection            1 (1)       --          --   1    1    1
                                                  1           30   61   67   63

Age group totals do not add up to total number of clinical trials (76) as some trials contributed to more than one age group.

\*Total number of preterm and term neonates.

Antibiotic class {#s3f}
----------------

The majority of antibiotics being investigated were beta-lactams (n=47, 62%), followed by other antibiotic classes (J01X, including vancomycin, telavancin and dalbavancin) (n=21, 28%). Macrolides or lincosamides (J01F) were the next most commonly studied antibiotic classes (n=14, 18%). Very few trials were investigating of tetracyclines (J01A) (n=4, 5%), sulphonamides and trimethoprim (J01E) (n=7, 9%), aminoglycosides (J01G) (n=2, 3%) or quinolones (J01M) (n=8, 11%). Two CTs (3%) did not specify the class of antibiotic being investigated. Sixteen (21%) trials were investigating more than one antibiotic; these trials counted towards more than one J01 category. The breakdown of J01 categories, as per WHO ATC/DDD classification,[@R11] is described in [table 1](#T1){ref-type="table"}.

Antibiotic pipeline {#s3g}
-------------------

Of the 37 antibiotics listed in the May 2016 edition of the Pew Charitable Trusts Antibiotic Pipeline (last accessed 10 June 2016),[@R12] as noted by the EMA Opinions and Decisions on Pediatric Investigation Plans, five had an agreed PIP: imipenem/cilastatin+relebactam, cadazolid, carbavance (meropenem+vaborbactam), eravacycline and solithromycin.[@R8] As of 8 November 2016, our search found that only 2 of these 37 antibiotics listed (carbavance and solithromycin) were being investigated in 1 and 2 ongoing CTs in paediatric patients, respectively ([table 4](#T4){ref-type="table"}). A PIP was agreed for carbavance in 2015 for treatment of Gram-negative infections, and for solithromycin in 2016 for the treatment of gonococcal infection, and later for treatment of anthrax, tularaemia and bacterial pneumonia. PIPs were agreed in 2015 for treatment of UTI and complicated IAI with eravacycline, and in 2016 for treatment of *Clostridium difficile* infection with cadazolid and of Gram-negative bacterial infection with imipenem/cilastin+relebactam.[@R13] Despite this, we could not identify any registered trials of these antibiotics in our search.

###### 

Comparison of antibiotic development pipeline in adults and children

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotic                           Phase     Manufacturer                  Indication                                                                           Drug development in adults   Paediatric Investigation Plan for drug development in Children   Number of open clinical trials in children
  ------------------------------------ --------- ----------------------------- ------------------------------------------------------------------------------------ ---------------------------- ---------------------------------------------------------------- --------------------------------------------
  WCK 4873                             Phase 1   Wockhardt                     Bacterial infection                                                                  ✓                            --                                                               --

  MGB -- BP -- 3                       Phase 1   MGB Pharma                    *Clostridiumdifficile* infection                                                     ✓                            --                                                               --

  OP0595                               Phase 1   Meiji Seika Pharma\           Bacterial infection                                                                  ✓                            --                                                               --
                                                 Fedora Pharmaceuticals                                                                                                                                                                                           

  BAL30072                             Phase 1   Basilea Pharmaceuticals       Multidrug-resistant Gram negatives                                                   ✓                            --                                                               --

  CRS3123                              Phase 1   Crestone                      Clostridium *difficile* infection                                                    ✓                            --                                                               --

  LCB01 -- 0371                        Phase 1   Legochem Biosciences          Bacterial infection                                                                  ✓                            --                                                               --

  TD -- 1607                           Phase 1   Theravance Biopharma          Acute skin infection, HAP, VAP, bacteraemia                                          ✓                            --                                                               --

  WCK 2349                             Phase 1   Wockhardt                     Bacterial infection                                                                  ✓                            --                                                               --

  WCK 771                              Phase 1   Wockhardt                     Bacterial infection                                                                  ✓                            --                                                               --

  Zidebactam+Cefepime                  Phase 1   Wockhardt                     cUTI, HAP, VAP                                                                       ✓                            --                                                               --

  TP -- 271                            Phase 1   Tetraphase Pharmaceuticals    CAP                                                                                  ✓                            --                                                               --

  Aztreonam -- Avibactam               Phase 2   Astrazeneca\                  cIAI                                                                                 ✓                            --                                                               --
                                                 Allergan                                                                                                                                                                                                         

  MRX -- 1                             Phase 2   MicuRx Pharmaceuticals        Acute skin infection (systemic)                                                      ✓                            --                                                               --

  Debio 1450                           Phase 2   Debiopharm International      Acute skin infection, Staphylococcus *spp*.-associated osteomyelitis                 ✓                            --                                                               --

  ETX0914                              Phase 2   Entasis Therapeutics          Uncomplicated gonorrhoea                                                             ✓                            --                                                               --

  P0L7080                              Phase 2   Polyphor                      Pseudomonas spp.-associated VAP, lower respiratory tract infection, bronchiectasis   ✓                            --                                                               --

  Brilacidin                           Phase 2   Cellceutix                    Acute skin infection (systemic)                                                      ✓                            --                                                               --

  Ceftaroline+avibactam                Phase 2   AstraZeneca\                  Bacterial infection                                                                  ✓                            --                                                               --
                                                 Allergan                                                                                                                                                                                                         

  CG400549                             Phase 2   Crystal Genomics Inc.         Acute skin infection, osteomyelitis                                                  ✓                            --                                                               --

  Finafloxacin                         Phase 2   MerLion Pharmaceuticals Pte   cUTI, cIAI, acute skin infection, pyelonephritis                                     ✓                            --                                                               --

  Geptidacin                           Phase 2   GlaxoSmithKline               cUTI, CAP, uncomplicated urogenital gonorrhoea                                       ✓                            --                                                               --

  Nemonoxacin                          Phase 2   TaiGen Biotechnology          CAP, acute skin infection, diabetic foot                                             ✓                            --                                                               --

  Ramoplanin                           Phase 2   Nanotherapeutics              Prevent recurrent *Clostridium difficile* infection                                  ✓                            --                                                               --

  Ridinilazole                         Phase 2   Summet Therapeutics           *Clostridium difficile*                                                              ✓                            --                                                               --

  Zabofloxacin                         Phase 3   Dong Wha Pharmaceuticals      CAP                                                                                  ✓                            --                                                               --

  S -- 6 49 266                        Phase 3   Shionogi                      HAP, VAP, cUTI, bloodstream infection                                                ✓                            --                                                               --

  Omadacycline                         Phase 3   Paratek Pharmaceuticals       CAP, cUTI, acute skin infection                                                      ✓                            --                                                               --

  Lefamulin                            Phase 3   Nabriva Therapeutics          CAP, HAP, VAP, acute skin infection, osteomyelitis, prosthetic joint infections      ✓                            --                                                               --

  Imipenem/cilastatin+relebactam       Phase 3   Merck & Co.                   cUTI, cIAI, HAP, VAP, acute pyelonephritis                                           ✓                            ✓                                                                --

  Iclaprim                             Phase 3   Motif Bio                     HAP, acute skin infection                                                            ✓                            --                                                               --

  Cadazolid                            Phase 3   Actelion Pharmaceuticals      *Clostridium difficile*                                                              ✓                            ✓                                                                --

  Taksta (fusidic acid)                Phase 3   Cempra                        Acute skin infection, prosthetic joint infection                                     ✓                            --                                                               --

  Carbavance (meropenem+vaborbactam)   Phase 3   Rempex Pharmaceuticals        cUTI, cIAI, HAP, VAP, febrile neutropaenia, bacteraemia, acute pyelonephritis\*      ✓                            ✓                                                                1

  Delafloxacin (Baxdela)               Phase 3   Melinta Therapeutics          Acute skin infections, CAP, cUTI                                                     ✓                            Waiver granted                                                   --

  Eravacycline                         Phase 3   Tetraphase Pharma             cIAI and cUTI                                                                        ✓                            ✓                                                                --

  Plazomicin                           Phase 3   Achaogen                      cUTI, HAP, VAP, cIAI, catheter-associated bloodstream infection\*                    ✓                            --                                                               --

  Solithromycin                        Phase 3   Cempra                        CAP, uncomplicated urogenital gonorrhoea, urethritis                                 ✓                            ✓                                                                2
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adapted from Pew Charitable Trusts 'Antibiotics currently in clinical development' pipeline (last accessed October 2016).[@R12]

\*Target carbapenem-resistant enterobacteriaceae.

CAP, community-acquired pneumonia; cIAI, complicated Intra-abdominal infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; VAP, ventilator-acquired pneumonia.

Discussion {#s4}
==========

Our search identified 76 clinical trials investigating one or more antibiotics recruiting children between 0 and 18 years of age. This is low in comparison with the number of ongoing trials in adults, despite children representing around a quarter of the global population.[@R14] A review of completed CTs in the USA between 2000 and 2010 identified a total of 4078 adult trials compared with just 294 that had recruited children.[@R16] In our study, the lack of trials recruiting neonates is striking. Just 23 of the 76 trials identified were recruiting neonates and remarkably just 8 CTs globally were recruiting preterm neonates. There are broadly two types of paediatric trials conducted globally: (1) pharmaceutical-led phase 1/2 PK and safety trials (n=17) being conducted in the HIC setting, and (2) investigator-led, often pragmatic, late phase efficacy trials in the LMIC setting (n=34). Amongst these a greater proportion of ongoing trials are sponsored by non-profit organisations over industry (66% compared with 34%). As of April 2016, there were 17 antibiotic PIPs agreed by the EMA,[@R8] covering a range of indications, most commonly cSSTI, complicated IAI (cIAI) and complicated UTI (cUTI).[@R13] In contrast, treatments for respiratory and systemic infections, the most common clinical indications for antibiotics in paediatrics, are not currently being evaluated.[@R14] Thirty-seven antibiotics are currently being developed in adults, yet to our knowledge, just two of these are being studied in children. Some classes of antibiotics that may be of higher risk for children (tetracyclines and fluoroquinolones) may not be pursued as aggressively for paediatric approvals due to well-recognised issues of toxicity, particularly when safer alternatives are widely available. Given that Gram-negative sepsis is a growing problem in neonates, with a significant increase in the proportion of multiresistant Gram-negative pathogens,[@R15] the substantial lag time between the submission date (for PIP or waiver) and declared completion date of PK studies in adults is a real concern, although there is value in generating substantial safety data in adults prior to exposing children and newborns to potentially toxic new agents.

In 2013, a similar review of European paediatric clinical trials identified 31 trials of antibiotics approved for adults by the EMA in 2000 that were recruiting children in Europe (compared with the 22 trials we found recruiting in Europe). They included both published and ongoing trials, which likely accounts for the higher number of trials reported. They similarly found a very small proportion of neonatal trials (2 of 31), as well as a greater proportion of efficacy-based trials.[@R9] A review of interventional trials registered with *ClinicalTrials.gov* between 2007 and 2010 found that only 17% had recruited children below 18 years of age.[@R17] A similar review of antimicrobial CTs conducted in the USA between 2000 and 2012 reported that just 5% had recruited only children compared with 74% that recruited only adults, and that, as we have found, the trials were sponsored primarily by non-profit organisations (60% vs 30% by industry).[@R14] In our search of global trials, 39% of registered CTs reported collection of PK data in comparison with a 2009 paediatric PK research review that reported 24% of registered CTs would be collecting PK data.[@R18]

The search strategy used has some limitations. Since the search was limited to clinical trials registered with *ClinicalTrials.gov*, it is possible other open or ongoing trials registered with alternative platforms (eg, the WHO International Clinical Trials Registry Platform) will have been missed. Together with *ClinicalTrials.gov*, these could help to establish the entirety of current clinical research in this field. We did, however, search EudraCT and found no further studies beyond those captured on *ClinicalTrials.gov*. Our search was also limited to open CTs, thereby missing active but not yet recruiting trials and those that had already closed to recruitment. The information recorded for each trial registered with *ClinicalTrials.gov* is updated by the trial investigators, and therefore relies on them to periodically update the registry. Occasionally, information such as recruitment status might not be updated in real time.

Concerns around the growing threat of antimicrobial resistance have prompted several new initiatives. In 2016, the EMA published a draft concept paper to propose the development of an addendum to the guideline on the evaluation of new antibacterial products for treatment of bacterial infections in children.[@R19] At the same time, the Clinical Trials Transformation Initiative is currently focused on the identification of key barriers in the conduct of paediatric antibacterial CTs, which hamper their successful implementation into clinical practice.[@R20] Recent evidence states that, overall, antibiotic CTs make up less than 1% of all registered paediatric CTs and that trial completion is slow, with an average time to completion of around 2 years.[@R21] There are specific areas where the design and conduct of paediatric antibiotic CTs can be harmonised and simplified, such as the standardisation of the inclusion and exclusion criteria for specific clinical infection syndromes, and improved bridging of safety and efficacy data from other age groups; these advances could improve trial conduct and efficiency in children.[@R22]

Conclusions {#s5}
===========

This review highlights that very few paediatric antibiotic CTs are being conducted globally, particularly in neonates. There is a marked disparity between antibiotic drug development programmes in adults and children. Many issues contribute to the difficulties in conducting paediatric antibiotic clinical trials. The lack of regulatory guidance, vulnerability of this population, issues with informed consent and assent and lack of research-experienced hospital personnel all present challenges in study design, delivery and recruitment. Delays in the initial start-up of CTs in paediatrics due to paediatric-specific protocol issues and complicated ethical approval continue to discourage both academic and pharmaceutical interest. The limited data presented here suggest that the dismal state of paediatric antibiotic research continues. Earlier collaboration between global academic research networks and pharmaceutical companies is now vital to accelerate progress.
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